Format

Send to

Choose Destination
JAMA Neurol. 2018 May 1;75(5):608-619. doi: 10.1001/jamaneurol.2017.5135.

Proximity to Parental Symptom Onset and Amyloid-β Burden in Sporadic Alzheimer Disease.

Author information

1
Department of Psychiatry, McGill University, Montreal, Quebec, Canada.
2
Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.
3
Douglas Mental Health University Institute, Studies on Prevention of Alzheimer's Disease (StOP-AD) Centre, Montreal, Quebec, Canada.
4
McGill Centre for Integrative Neuroscience, McGill University, Montreal, Quebec, Canada.
5
Department of Neurology, Washington University School of Medicine, St Louis, Missouri.
6
Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri.
7
Department of Radiology, Washington University School of Medicine, St Louis, Missouri.
8
Wisconsin Alzheimer's Institute, University of Wisconsin-Madison School of Medicine and Public Health, Madison.
9
Alzheimer's Disease Research Center, University of Wisconsin-Madison School of Medicine and Public Health, Madison.

Abstract

Importance:

Alzheimer disease (AD) develops during several decades. Presymptomatic individuals might be the best candidates for clinical trials, but their identification is challenging because they have no symptoms.

Objective:

To assess whether a sporadic parental estimated years to symptom onset calculation could be used to identify information about amyloid-β (Aβ) levels in asymptomatic individuals with a parental history of AD dementia.

Design, Setting, and Participants:

This cohort study analyzed Aβ1-42 in cerebrospinal fluid (CSF) specimens from 101 cognitively normal individuals who had a lumbar puncture as part of the Presymptomatic Evaluation of Novel or Experimental Treatments for Alzheimer Disease (PREVENT-AD) cohort from September 1, 2011, through November 30, 2016 (374 participants were enrolled in the cohort during this period). The study estimated each participant's proximity to his/her parent's symptom onset by subtracting the index relative's onset age from his/her current age. The association between proximity to parental symptom onset and Aβ levels was then assessed using apolipoprotein E ε4 (APOE4) status and sex as interactive terms. These analyses were performed again in 2 independent cohorts using CSF and Pittsburgh compound B carbon 11-labeled positron emission tomography (PIB-PET) Aβ biomarkers: the Adult Children Study (ACS) and the Wisconsin Registry for Alzheimer Prevention (WRAP) cohorts.

Main Outcomes and Measures:

The association between proximity to parental symptom onset and Aβ burden in asymptomatic individuals with a parental history of sporadic AD.

Results:

The present analysis included a subset of 101 PREVENT-AD individuals (mean [SD] age, 61.8 [5.1] years; 30 [29.7%] male), 128 ACS participants (112 participants underwent CSF measurement: mean [SD] age, 63.4 [5.1] years; 31 [27.7%] male; and 107 underwent PIB-PET: mean [SD] age, 64.6 [5.3] years; 27 [25.2%] male), and 135 WRAP participants (85 participants underwent CSF measurement: mean [SD] age, 59.9 [6.0] years; 27 [31.8%] male; and 135 underwent PIB-PET: mean [SD] age, 59.6 [6.1] years; 43 [31.9%] male). In the PREVENT-AD cohort, individuals approaching their parent's onset age had lower CSF Aβ1-42 levels (range, 402-1597; B = -9.09, P = .04). This association was stronger in APOE4 carriers (B = -17.9, P = .03) and women (B = -19.8, P = .02). In the ACS cohort, the main association was replicated using PIB-PET data, and the sex interaction was replicated using CSF and PIB-PET data. In the WRAP cohort, the results were not replicated using cross-sectional data, but the main association and the APOE interaction were replicated using PIB-PET longitudinal data.

Conclusions and Relevance:

These results suggest that proximity to parental symptom onset may help estimate Aβ biomarker changes in women or APOE4 carrier asymptomatic individuals with a parental history of sporadic AD.

PMID:
29482212
PMCID:
PMC5885216
[Available on 2019-02-26]
DOI:
10.1001/jamaneurol.2017.5135

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center